Outsource API manufacturing to India for lower costs, GMP-compliant quality, scalable production, and faster time-to-market for pharma companies.

Construction is scheduled to commence in spring 2026, with both facilities anticipated to be fully operational by 2029.

AbbVie invests $380 million to build two new API manufacturing facilities in North Chicago while Bora Pharmaceuticals Co., Ltd. and GSK have renewed a five-year global manufacturing partnership.

Feb 23 (Reuters) - AbbVie on Monday said it would invest $380 million to build two new active pharmaceutical ingredient ...

AbbVie (NYSE: ABBV) today announced a new $380 million investment to build two new active pharmaceutical ingredient (API) manufacturing facilities at its current North Chicago, Illinois, campus. These ...

As the pharmaceutical industry continues to evolve in the wake of pandemic-driven disruptions and heightened regulatory scrutiny, the role of the top pharmaceutical API manufacturer has taken on ...

How integrated pharmaceutical manufacturing helps CDMOs simplify scale-up, reduce complexity, and move from raw materials to finished dosage forms faster.

"Soter Bio was built to support advanced therapeutic programs that depend on reliable, rapid, scalable input materials," said Mike Stewart, Founder and CEO of Soter Bio. "Partnering with Cellipont ...

The pharmaceutical manufacturing market is poised for growth by leveraging advanced technologies, digital platforms, and robust supply chain strategies. Opportunities arise in adopting ...

MUSCAT, FEB 23As Oman advances its ambitions under Oman Vision 2040, the spotlight is increasingly shifting from mere production to how ...

The PreCheck program aims to strengthen the U.S. pharmaceutical supply chain by streamlining regulatory assessments for domestic manufacturing facilities. The initiative encourages onshoring by ...